title: Angiotensin II AT1 receptor blockade normalizes CD11b+ monocyte production in bone marrow of hypercholesterolemic monkeys.
abstract: The enhanced production of monocytes expressing pro-inflammatory markers such as the integrin CD11b in patients with hypercholesterolemia may promote vascular inflammation and exacerbate atherogenesis. The objective of the present study was to determine whether hypercholesterolemia stimulates the production of CD11b(+) monocytes in bone marrow, and whether the renin-angiotensin system participates in this process and thus provides a target for therapeutic intervention. The dietary induction of hypercholesterolemia in adult male cynomolgus monkeys was accompanied by increased bone marrow cellularity and elevated peripheral blood and bone marrow monocyte CD11b expression. Isolated bone marrow CD34(+) hematopoietic stem cells (HSCs) evaluated by in vitro functional assays exhibited enhanced myeloproliferative capacity and differentiation into CD11b(+) monocytes. Treatment of hypercholesterolemic monkeys with the angiotensin II AT(1) receptor blocker losartan for 15 weeks reduced bone marrow cellularity, suppressed peripheral blood and bone marrow monocyte CD11b expression, and normalized CD34(+) cell function assays. All variables returned to pretreatment levels 6 weeks after discontinuation of losartan treatment. Hypercholesterolemia was associated with increased CD34(+) cell AT(1) receptor expression and an exaggerated in vitro myeloproliferative response to angiotensin II stimulation that positively correlated to plasma LDL concentrations. In vitro exposure to native low-density lipoproteins (LDL) also increased CD34(+) cell AT(1) receptor expression and the myeloproliferative response to angiotensin II stimulation in a dose-dependent and receptor-mediated manner. Our data provide support for a positive regulatory role of plasma LDL on AT(1) receptor-mediated HSC differentiation and the production of pro-atherogenic monocytes. LDL-regulated HSC function may explain in part hypercholesterolemia-induced inflammation as well as the anti-inflammatory and anti-atherosclerotic effects of AT(1) receptor blockers.
authors: Hypertension and Vascular Research Center, Wake Forest University Health Sciences, Winston-Salem, NC 27157, United States. bstrawn@wfubmc.edu
authors: William B
authors: WB
authors: Strawn
authors: Carlos M
authors: CM
authors: Ferrario
mesh_terms: D000804:Angiotensin II / Q000097:blood; D000818:Animals; D018952:Antigens, CD34 / Q000032:analysis; D001854:Bone Marrow Cells / Q000378:metabolism*; D039481:CD11b Antigen / Q000096:biosynthesis*; D002784:Cholesterol / Q000097:blood; D002791:Cholesterol, Dietary / Q000008:administration & dosage; D006937:Hypercholesterolemia / Q000378:metabolism*; D007963:Leukocytes, Mononuclear / Q000187:drug effects; D019808:Losartan / Q000627:therapeutic use; D008252:Macaca fascicularis; D008297:Male; D044140:Receptor, Angiotensin, Type 1 / Q000187:drug effects*; D012084:Renin-Angiotensin System / Q000502:physiology
chemical_list: D018952:Antigens, CD34; D039481:CD11b Antigen; D002791:Cholesterol, Dietary; D044140:Receptor, Angiotensin, Type 1; D000804:Angiotensin II; D002784:Cholesterol; D019808:Losartan
references: Circulation. 1999 Nov 23;100(21):2131-4
references: 10571970
references: Arterioscler Thromb Vasc Biol. 2007 Feb;27(2):380-6
references: 17158350
references: Circulation. 2000 Apr 4;101(13):1586-93
references: 10747353
references: Cytometry. 2000 May 1;40(1):26-31
references: 10754514
references: Stem Cells. 2000;18(4):287-94
references: 10924095
references: Ann Med. 2000 Sep;32(6):386-9
references: 11028685
references: Diabetes Obes Metab. 2000 Aug;2(4):223-8
references: 11225655
references: J Am Coll Cardiol. 2001 Nov 15;38(6):1662-7
references: 11704378
references: Clin Pharmacol Ther. 2002 Jan;71(1):89-98
references: 11823761
references: J Hum Hypertens. 2002 May;16 Suppl 2:S7-12
references: 11967727
references: Stem Cells. 2002;20(3):269-71
references: 12004086
references: J Clin Invest. 2002 Dec;110(12):1859-68
references: 12488436
references: Diabetes Care. 2003 May;26(5):1540-4
references: 12716819
references: J Lipid Res. 2003 Jul;44(7):1332-40
references: 12730301
references: Am J Primatol. 2003 Sep;61(1):3-12
references: 12966515
references: Blood. 2004 Feb 1;103(3):878-85
references: 14525791
references: Br J Haematol. 2004 Jul;126(1):120-6
references: 15198742
references: J Cell Physiol. 1979 May;99(2):233-8
references: 222784
references: J Lipid Res. 1985 Dec;26(12):1476-80
references: 4086949
references: Am J Pathol. 1989 Aug;135(2):369-77
references: 2675618
references: Arteriosclerosis. 1989 Nov-Dec;9(6):848-55
references: 2590064
references: Blood. 1990 Dec 15;76(12):2483-92
references: 1702327
references: Arterioscler Thromb. 1991 Jul-Aug;11(4):985-94
references: 2065049
references: Circulation. 1997 Jan 21;95(2):473-8
references: 9008466
references: J Am Coll Cardiol. 1997 Nov 1;30(5):1212-7
references: 9350917
references: Tissue Antigens. 1998 Feb;51(2):141-55
references: 9510370
references: J Immunol. 2006 May 1;176(9):5577-86
references: 16622027
references: Regul Pept. 2006 May 15;134(2-3):69-74
references: 16530863
references: Adv Cardiol. 2007;44:315-30
references: 17075218
references: J Hypertens. 1999 Dec;17(12 Pt 2):1933-9
references: 10703892